- Push-out Score determined
- After just a few days in the position
- Rob Kelley taking over
(exechange) — Menlo Park, California, December 8, 2021 — Brian Blaser, chief executive of Talis, leaves. As announced by Talis Biomedical Corp. in a news release on Wednesday, December 8, 2021, Brian J. Blaser leaves his post as chief executive officer at the medical diagnostics company, after just a few days in the role, effective immediately.
Brian Blaser’s duties as CEO will be taken over by Robert (Rob) Kelley, most recently Chief Commercial Officer at Talis Biomedical Corp.
Brian Blaser’s departure from the CEO post is explained as follows. Talis said: “Brian Blaser has stepped down from the positions of President, Chief Executive Officer and Director, due to personal matters.”
Precise information regarding Brian Blaser’s future plans was not immediately available.
Share price decline since March 2021
The announcement follows a decline in Talis Biomedical Corp.’s share price of 72% since March 2021.
In the position of CEO since 2021
Brian Blaser became CEO of the Company in 2021.
On November 15, 2021, Talis Biomedical announced the appointment of Brian Blaser to President, Chief Executive Officer and Director, effective December 1, 2021.
Blaser has more than 25 years of senior leadership experience in the in-vitro diagnostics industry, including 17 years at Abbott Laboratories.
During his tenure at Abbott, Blaser most recently served as EVP of Diagnostics Products overseeing the company’s multi-billion-dollar global diagnostics organization, including its core laboratory, point of care, rapid diagnostics and molecular diagnostics businesses.
Earlier in his career, Blaser held key leadership positions in operations, finance and engineering with the Ortho-Clinical Diagnostics division of Johnson & Johnson, Eastman Kodak and General Motors.
Blaser holds a Bachelor of Science in Mechanical Engineering Technology from the University of Dayton and a Master of Business Administration from the Rochester Institute of Technology.
At the time of Brian Blaser’s appointment as Chief Executive Officer at Talis, he stated: “I am honored to lead Talis through this important phase of growth and believe we have a unique product and opportunity to make an enduring impact for infectious disease patients at the point of care. I look forward to working alongside the Talis employees, senior leadership team and Board to achieve the company’s bold mission and business objectives.”
Push-out Score determined
The Push-out Score™ determined by exechange gauges the pressure surrounding Brian Blaser’s move on a scale of 0 to 10.
exechange reached out to Talis and offered the company the opportunity to comment on the score.
Read the full story in the exechange report 50.2021 ($).